Case report

**Legionella** in a patient with rheumatoid arthritis receiving abatacept

Patricia Novas Vidal, Silvia González Díez, and Javier Velasco Montes *

Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla, Santander, Spain

**ABSTRACT**

Abatacept is a new drug available for refractory rheumatoid arthritis (RA), as other biologic therapies this drug is not free of potentially serious adverse events. We present a case of a 73-year-old patient treated with abatacept who suffered a Legionella pneumophila type 1 pneumonia.

**INTRODUCTION**

Common treatments for rheumatoid arthritis (RA) include traditional antirheumatic disease-modifying drugs (DMARD) such as methotrexate and biologic agents, such as TNF (tumor necrosis factor) inhibitors. In spite of the fact that these therapeutic options benefit a lot of patients, a significant proportion does not respond to anti-TNF therapy and other present a diminished response to it with time. In addition, a subgroup of patients presents drug-related toxicity that obliges the clinician to suspend treatment. Other treatments have recently been introduced to the population of patients that have an inadequate response to anti-TNF treatment. These treatments have mechanisms of action different than traditional DMARD and anti-TNF agents.

Abatacept is a soluble modulator of costimulation of human origin, directed selectively against the costimulating CD80/CD86:CD28 signal, necessary for activation of T cells. In the ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF Inadequate responders), efficacy and security of abatacept in patients with active RA and inadequate response to anti-TNF treatment was measured. At 6 months, the double blind phase of this trial provided the first clues that supported this treatment strategy in TNF inhibitor-non responding patients and that demonstrated significant improvement, after treatment with abatacept, in signs and symptoms, physical function, and quality of life. Recently, the findings after 2 years of treatment with this drug have been presented and have confirmed the maintained beneficial effects observed at 6 months.

The incidence of severe infections stands out among the adverse events described with this treatment (5 of every 100 patients per year). Pneumonia is among the most frequent infections (incidence over 0.5% of patients).

**CASE REPORT**

We present the case of a 73-year-old woman without any history of addiction, with a history of arterial hypertension and mild chronic obstructive pulmonary disease for the past 10 years, as well as seronegative RA since 1980 (28 years since onset), without any extra-articular complications. Since her diagnosis she had been treated with gold salts, non-steroidal anti-inflammatory drugs, steroids and, sequentially, with leflunomide, etanercept, adalimumab, and infliximab (12 months with each), suspended due to lack of efficacy in the control of joint symptoms. At the moment of presentation, the patient was being treated with prednisolone (4 mg PO), methotrexate...


